Hypoxic cells in solid tumors are resistant to killing by ionizing radiation, and are thought to limit the success of radiotherapy. Many different methods have been designed to reduce or eliminate the hypoxic cell problem, yet no convenient or accurate method is currently available to actually measure hypoxic cells. Techniques to quantify cellular hypoxia are now being developed based primarily on the preferential metabolism and binding of fluorescent nitroheterocycles by hypoxic cells. Fluorscence- activated cell sorting (FACS) allows the fluorscence of individual cells to be measured, and this estimate of oxygenation can be correlated with viability measurements and biochemical analyses of cells sorted according to their flurorescence intensity. The feasibility of this method has been demonstrated in single cells and spheroids, and will now be extended to mouse tumor models. In addition, using the fluorescent probe AF-2, studies will continue on reasons for heterogeneity of AF-2 binding in multicell spheroids and tumors. New probes will be evaluated in vitro and in vivo, in the search for more fluorescent, less toxic nitroheterocycles, and for other fluorescent markers which may localize in hypoxic microregions in tumors. Finally, the roles of necrosis and transient hypoxia in binding of hypoxia probes in tumors will be addressed. In addition to FACS, a newly developed fluorescence image processing system (FIPS) will be used to measure fluorescence in frozen sections of tumors of spheroids, thus providing the capability of 3-dimensional reconstruction of the location of hypoxic tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037879-06
Application #
3175779
Study Section
Radiation Study Section (RAD)
Project Start
1984-03-01
Project End
1990-02-28
Budget Start
1989-03-01
Budget End
1990-02-28
Support Year
6
Fiscal Year
1989
Total Cost
Indirect Cost
Name
British Columbia Cancer Agency
Department
Type
DUNS #
209137736
City
Vancouver
State
BC
Country
Canada
Zip Code
V5 1L3
Nordsmark, Marianne; Loncaster, Julie; Aquino-Parsons, Christina et al. (2006) The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother Oncol 80:123-31
Nordsmark, Marianne; Loncaster, Juliette; Aquino-Parsons, Christina et al. (2003) Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol 67:35-44
Olive, Peggy L; Banath, Judit P; Durand, Ralph E (2002) The range of oxygenation in SiHa tumor xenografts. Radiat Res 158:159-66
Olive, P L; Luo, C-M; Banath, J P (2002) Local hypoxia is produced at sites of intratumour injection. Br J Cancer 86:429-35
Olive, P L; Durand, R E; Banath, J P et al. (2001) Analysis of DNA damage in individual cells. Methods Cell Biol 64:235-49
Partridge, S E; Aquino-Parsons, C; Luo, C et al. (2001) A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. Int J Radiat Oncol Biol Phys 49:575-80
Olive, P L; Banath, J P; Aquino-Parsons, C (2001) Measuring hypoxia in solid tumours--is there a gold standard? Acta Oncol 40:917-23
Olive, P L; Aquino-Parsons, C; MacPhail, S H et al. (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61:8924-9
Oloumi, A; MacPhail, S H; Johnston, P J et al. (2000) Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res 60:5747-53
Olive, P L; Durand, R E; Raleigh, J A et al. (2000) Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer 83:1525-31

Showing the most recent 10 out of 62 publications